| pubmed-article:10805227 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10805227 | lifeskim:mentions | umls-concept:C0021311 | lld:lifeskim |
| pubmed-article:10805227 | lifeskim:mentions | umls-concept:C0021758 | lld:lifeskim |
| pubmed-article:10805227 | lifeskim:mentions | umls-concept:C1456820 | lld:lifeskim |
| pubmed-article:10805227 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:10805227 | lifeskim:mentions | umls-concept:C0683598 | lld:lifeskim |
| pubmed-article:10805227 | lifeskim:mentions | umls-concept:C0033268 | lld:lifeskim |
| pubmed-article:10805227 | lifeskim:mentions | umls-concept:C1554184 | lld:lifeskim |
| pubmed-article:10805227 | lifeskim:mentions | umls-concept:C0205373 | lld:lifeskim |
| pubmed-article:10805227 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:10805227 | pubmed:dateCreated | 2000-8-2 | lld:pubmed |
| pubmed-article:10805227 | pubmed:abstractText | To determine the effect of interleukin 4 (IL-4) administration in a live sepsis model characterised by high-level production of tumour necrosis factor a (TNF-alpha), mice infected systemically with lethal or sublethal inocula of Pseudomonas aeruginosa were given the recombinant cytokine at different times before infection. Improved survival and decreased TNF-alpha production were observed in lethally infected mice treated with the cytokine 1 day before challenge. In contrast, increased mortality and overproduction of TNF-alpha were observed in sublethally infected mice given IL-4 at the time of infection. | lld:pubmed |
| pubmed-article:10805227 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10805227 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10805227 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10805227 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10805227 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10805227 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10805227 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10805227 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10805227 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10805227 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:10805227 | pubmed:issn | 1043-4666 | lld:pubmed |
| pubmed-article:10805227 | pubmed:author | pubmed-author:VaccaCC | lld:pubmed |
| pubmed-article:10805227 | pubmed:author | pubmed-author:FiorettiM CMC | lld:pubmed |
| pubmed-article:10805227 | pubmed:author | pubmed-author:GiampietriAA | lld:pubmed |
| pubmed-article:10805227 | pubmed:author | pubmed-author:PuccettiPP | lld:pubmed |
| pubmed-article:10805227 | pubmed:author | pubmed-author:CampanileFF | lld:pubmed |
| pubmed-article:10805227 | pubmed:author | pubmed-author:GrohmannUU | lld:pubmed |
| pubmed-article:10805227 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10805227 | pubmed:volume | 12 | lld:pubmed |
| pubmed-article:10805227 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10805227 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10805227 | pubmed:pagination | 417-21 | lld:pubmed |
| pubmed-article:10805227 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:10805227 | pubmed:meshHeading | pubmed-meshheading:10805227... | lld:pubmed |
| pubmed-article:10805227 | pubmed:meshHeading | pubmed-meshheading:10805227... | lld:pubmed |
| pubmed-article:10805227 | pubmed:meshHeading | pubmed-meshheading:10805227... | lld:pubmed |
| pubmed-article:10805227 | pubmed:meshHeading | pubmed-meshheading:10805227... | lld:pubmed |
| pubmed-article:10805227 | pubmed:meshHeading | pubmed-meshheading:10805227... | lld:pubmed |
| pubmed-article:10805227 | pubmed:meshHeading | pubmed-meshheading:10805227... | lld:pubmed |
| pubmed-article:10805227 | pubmed:meshHeading | pubmed-meshheading:10805227... | lld:pubmed |
| pubmed-article:10805227 | pubmed:meshHeading | pubmed-meshheading:10805227... | lld:pubmed |
| pubmed-article:10805227 | pubmed:meshHeading | pubmed-meshheading:10805227... | lld:pubmed |
| pubmed-article:10805227 | pubmed:meshHeading | pubmed-meshheading:10805227... | lld:pubmed |
| pubmed-article:10805227 | pubmed:meshHeading | pubmed-meshheading:10805227... | lld:pubmed |
| pubmed-article:10805227 | pubmed:meshHeading | pubmed-meshheading:10805227... | lld:pubmed |
| pubmed-article:10805227 | pubmed:meshHeading | pubmed-meshheading:10805227... | lld:pubmed |
| pubmed-article:10805227 | pubmed:year | 2000 | lld:pubmed |
| pubmed-article:10805227 | pubmed:articleTitle | Dual effect of IL-4 on resistance to systemic gram-negative infection and production of TNF-alpha. | lld:pubmed |
| pubmed-article:10805227 | pubmed:affiliation | Department of Experimental Medicine, University of Perugia, Italy. | lld:pubmed |
| pubmed-article:10805227 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10805227 | lld:pubmed |
